Funding Opportunities

This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator initiated Research Project Grant (R01) or equivalent application.

To support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR)

This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator initiated Research Project Grant (R01) or equivalent application.

The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate transition of highly qualified dentists from NIH Intramural postdoctoral research positions to extramural academic tenure-track or equivalent faculty positions at eligible institutions. The award will provide support for two years of mentored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research funding at the extramural institution.

To support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR)

We invite research grant applications that utilize New Approach Methodologies (NAMs) and Non-Animal Technologies (NATs)—such as archived human joint tissues, organoids, tissue chips, advanced in vitro systems, computational and mathematical models, and non-invasive imaging techniques. When appropriately justified, applications may also incorporate combinations of these approaches with animal models, including genetically modified mouse models and underutilized large animal models, to investigate the biological mechanisms driving the initiation and progression of osteoarthritis (OA).

This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator initiated Research Project Grant (R01) or equivalent application.

The Prize is awarded annually to one young scientist for the most outstanding neurobiological research based on methods of molecular, cellular, systems, or organismic biology conducted during the past 3 years. Prize money: US$25,000

This fellowship awards up to $60,000 to promote women in science and provides an opportunity to a female ORS member who is a recent PhD in science or engineering to conduct research in the field of orthopaedic technology.

Elevating Early-Career Global Innovators The Peter Sheehan Young Innovator Award honors early-career scientists whose research is pushing the boundaries of tissue regeneration, clinical diagnostics, therapeutics, and diabetic limb preservation. Dr. Peter Sheehan dedicated his career to transforming the lives of patients with diabetes-related complications through translational science. This Award continues his legacy by identifying and elevating the next generation of researchers whose work demonstrates strong potential for clinical impact.

Neuromuscular Research Grants The foundation offers neuromuscular research grants designed to support exploratory or high-risk/high-reward research for mid-career or established researchers doing research in muscle and nerve disorders. Applications should directly relate to a muscle and nerve disorder covered by the AANEM.

The PhRMA Foundation’s Postdoctoral Fellowship in Translational Medicine supports individuals (U.S. and non-U.S. citizens) engaged in a multidisciplinary, collaborative research training program at an accredited U.S. university that will extend their credentials in translational medicine.

The W.M. Keck Foundation seeks projects that aim to deliver pioneering and fundamental scientific discoveries in important and emerging areas of research. Keck funds high-impact research in basic physical, life, and biomedical sciences, including instrumentation development and engineering approaches in service of answering basic scientific questions. Institutions may nominate up to eight concept papers. Funding of up to $1.3 million is available. Applications are due to the Office of the Vice President for Research by April 27, 2026.

By March 11: If you would like your 2-page proposals to be reviewed prior to the official submission, they must be submitted to Meagan Ramsey (maramsey@med.umich.edu), Director of the Weil Institute Proposal Development Team, by this date. Please email Meagan in advance to let her know that you would like her to review your proposal.

Now in its tenth year, the Frankel CVC Innovation Challenge is an annual pitch competition where teams can win funding for ideas that impact cardiovascular care. In addition, Just Do It awards are selected for low-cost, low-complexity ideas. Ideas are welcome from anyone at U-M with a cardiovascular innovation: faculty, staff, trainees, and patients. As always, all innovative ideas that impact cardiovascular care will be accepted for the 2026 Innovation Challenge.

For the current funding cycle (2026), the Hub will operate under an RFP-based submission and review process rather than a rolling process. In addition, the maximum allowable budget will be temporarily capped at $25,000 to accommodate a backlog of proposals. Research teams and technology managers are encouraged to minimize budget requests and maximize project efficiency – as this will be an important new review criteria. To address these concerns, it is best to develop your proposal around a “minimal viable project” – consisting of a couple key technical or customer de-risking milestones needed to evaluate the suitability of the technology for an intended application.

Funding amount: Up to $250,000 in direct costs with cost share requirement Contact: Meghan Cuddihy (mcuddihy@umich.edu)

Contact Alex Srnka (asrnka@umich.edu) and she will assist with submitting the pre-proposal. $150K / 1yr funding

The Bridge to Success for Early Career Investigators grant program provides ‘bridge’ funding to promising early career sleep and circadian scientists who plan to resubmit an application for a mentored, federal career development grant that was previously not funded. Applicants must be at a critical juncture where research funding is needed to stay in the sleep field. The Bridge to Success Grant for Early Career Investigators will give scientists the time and funding needed to revise and resubmit their mentored, federal career development grant application.

The Mary Kay Ash Foundation funds innovative translational research of cancers affecting women (ovarian, uterine, breast, endometrial, or cervical cancer - among others). Translational research is broadly defined as research that will provide a scientific link between the laboratory research and the clinic. Ultimately, such research would lead to improvement in diagnosis, prognosis, prevention, or treatment of the cancer. Funding Available: up to $100,000 - over two years (combined and indirect costs) Internal Submission Deadline: Monday, December 8, 2025 at 4:59 pm

The Physician Scientist Training Grant supports early-career physician-scientists committed to advancing sleep and circadian science research. This grant provides protected time for physician-scientists to engage in a mentored research project, allowing them to build a track record of funding, become competitive for larger grants, and prepare for larger studies. Research Focus: This request for applications for the Physician Scientist Training Grant is open to mentored projects that address one or more important unanswered scientific questions related to sleep and circadian science, sleep disorders and/or sleep health.

Studio Red/Go Red for Women Fund/AHA invites researchers, clinicians, entrepreneurs, and innovators to submit pre-proposals for funding consideration to advance groundbreaking research and novel solutions in women’s health. Selected pre-proposals will be invited to submit full proposals for competitive grants that aim to close critical knowledge and care gaps.

The purpose of this Request for Proposal (RFP) announcement is to fund research focused on the prevalence and treatment of cardiovascular, kidney and metabolic disease in cancer patients and survivors. Who we’re looking for: Proposals are encouraged from multidisciplinary researcher teams with expertise in two or more of the following areas: cardio-oncology, cardiovascular, kidney and metabolic disease, health economics, epidemiology, and biostatistics with experience in causal inference methods, machine learning, and cardiovascular research. Organizations that are currently funded through other American Heart Association funding mechanisms can apply.

Promotes the development of new clinician scientists who have demonstrated success as both a clinician and a researcher. Allows investigators to spend dedicated time in research for a period of up to five years to develop a long and productive career in academic surgery.

The American Heart Association continuously seeks innovative ideas to address the most pressing issues impacting cardiovascular and brain health. To that end, the Association is pleased to announce the Rapid Impact Research Award program, which will support early and mid-career investigators proposing innovative research that aligns with the Association’s mission. Novel basic, clinical and/or population health proposals are invited in the following three priority areas of research.

Bioprinting offers the potential to construct highly complex and patient-specific tissues and organs as well as tissue interfaces. However, one of the major bottlenecks that hinders bioprinting of fully functional tissues and organs is the lack of diverse bioinks that can mimic the dynamic properties of the native tissue. This project aims to investigate materials design strategies to create smart bioinks to address this gap, and to apply these bioinks for printing of fully functional osteochondral tissues. One of the fundamental research questions that they hope to answer revolves around how to instruct stem cells to differentiate spatially within a 3D-bioprinted construct towards osteochondral tissue formation.

With the International Network of Excellence (INE) Program, the Leducq Foundation looks to support original and outstanding research in the areas of the foundation’s mission, namely, cardiovascular and neurovascular disease. Applicants are encouraged to think innovatively and to propose bold new ideas. The programs promotes internationally collaborative basic, translational, and clinical research in cardiovascular and neurovascular disease.

The Biocodex Microbiota Foundation founds research projects focused on human gut microbiota related to health and disease. Every year, the call for proposals covers a specific theme chosen by an International Scientific Committee. Either clinical or fundamental research proposals can be submitted. The maximal duration of the project will be 3 years.

The Investigator Initiated Research Award Program from the Blue Cross Blue Shield of Michigan Foundation supports doctoral-level researchers focused on: addressing critical gaps in health-related research, examining factors that may prevent or reduce risk for disease, examining associations and cause and effect relationships between health variables, secondary data analysis of large datasets, health care cost-analysis studies, and robust evaluation projects and feasibility studies to test the implementation of innovative interventions to improve health outcomes.

The CDA is a three-year grant totaling $200,000 that supports personnel and/or research expenses, and travel to attend the Conquer Cancer Grants and Awards Ceremony at the ASCO Annual Meeting. The number of CDA grants in each funding cycle is not predetermined by Conquer Cancer. Conquer Cancer is committed to funding the most meritorious applications in all areas of cancer research.

The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the MMRF 2025 Scholars Program. The goal of this initiative is to engage and support the careers of promising clinical and/or laboratory investigators in the field of multiple myeloma research with significant connections to the patient population for multiple myeloma. The Scholars Program will support the awardee from post-doctoral training to first faculty-track position.

The overarching purpose of the award is two-fold: to support a research project in bleeding disorders and their impact on women and girls. The project is to be one proposed by junior faculty or fellows who are pursuing careers in the following disciplines: Adult or Pediatric Hematology; a Women’s Reproductive Health specialty such as Obstetrics/Gynecology, Adolescent Medicine, Pediatric/Adolescent Gynecology, or another subspecialty for which a major focus is the care of women and girls with bleeding disorders; and 2) to foster and sustain widespread interest in translating research into clinical care that will ultimately improve the lives of affected women and girls.

The OVPR is collecting materials for this 2026 Blavatnik Award for Young Scientists, internal limited submission competition, in advance of the formal invitation from the New York Academy of Science (NYAS). If there are any changes to the program, including sponsor deadlines, we will update this page and contact all applicants.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that translate technology and therapeutic innovations from academic and other non-profit research sectors to the marketplace to advance the development of diagnostic and prevention tools or treatments for musculoskeletal, rheumatic, or skin diseases. It supports late-stage pre-clinical research and development, such as moving products towards regulatory approval for clinical testing or making the new lab technologies more practical to use in a clinical setting. It requires close collaboration between the original developers of these technologies and the SBCs.

The Burroughs Wellcome Fund launched the Career Awards at the Scientific Interface in 1999 to foster the early career development of researchers who are transitioning from training environments in the physical, mathematical, computational sciences and/or engineering into postdoctoral work in the biological sciences, and who are dedicated to pursuing a career in academic research.

Guided by a commitment to find a cure for prostate cancer, the Mike Slive Foundation for Prostate Cancer Research funds pilot grants for innovative research to allow researchers to establish proof-of-concept when applying for larger, highly competitive federal grants.

See link for guidelines of research interest areas.

The Leukemia & Lymphoma Society (LLS) is proud to announce the Discovery Grant Program (DGP): a research award program designed to encourage basic research, technological innovation, and informatics pipeline development that can lead to an understanding of blood cancer disease mechanisms, the development of improved methods for detecting and monitoring cancer progression, and the identification of novel therapeutic targets. This is a dedicated mechanism to encourage established investigators to explore the biology of blood cancer and support proof-of-concept studies that could initiate completely novel approaches to treatment.

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program.

The 2025 Grand Challenge will take place at Lilly’s headquarters in Indianapolis, IN on September 3rd and 4th, 2025. Selected participants will be invited to network with Lilly executives and scientists and compete for $100,000 USD in non-dilutive grant funding. Selected participants will also gain access to Lilly’s extensive scientific and business network to help advance their technologies. Researchers interested in applying must submit their application before June 27th, 2025.

Next Generation Grants are $150,000 research grants given annually to support promising researchers applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. While the Michelson Prizes are focused on research in the fields of immunology, vaccine, and immunotherapy discovery, applicants from the full spectrum of related disciplines, including clinical research, biochemistry, molecular biology, protein engineering, computer science, artificial intelligence/machine learning, biophysics, nanotechnology, etc., are encouraged to apply. $150,000 / 1-year grants to support research. The 2026 Next Generation Grants will be accepting applications from April 1, 2025 - June 22, 2025

The Divisions of Chemical, Bioengineering and Environmental Transport (CBET) and Civil, Mechanical, and Manufacturing Infrastructure (CMMI) in the Engineering Directorate of the National Science Foundation (NSF) are partnering with the Center for the Advancement of Science in Space, Inc. (CASIS) to solicit research projects in the fields of tissue engineering and mechanobiology that can utilize the International Space Station (ISS) National Lab to conduct research that will benefit life on Earth. Topics must fit the scope of either the Biomechanics and Mechanobiology Program or the Engineering of Biomedical Systems Program and must address fundamental engineering gaps.

The Office of Research on Women’s Health (ORWH) works in partnership with the NIH Institutes, Centers and Offices (ICOs), as well as with federal agencies and their offices to ensure that women's health research is an integral part of the larger scientific framework to enhance health and treat disease. The ORWH mission includes strengthening research relevant to diseases, disorders, and conditions that affect women and ensuring that research supported by NIH adequately addresses issues regarding women’s health.

The Pew Scholars Program in the Biomedical Sciences provides funding to young investigators of outstanding promise in science relevant to the advancement of human health. The program makes grants to selected academic institutions to support the independent research of outstanding individuals who are in their first few years of their appointment at the assistant professor level.

The Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on demand organs that do not require immunosuppressive drugs. The goal is to use patient cells or a biobank to quickly produce immune- and blood type-matched replacement organs, such as kidneys, hearts, and livers. If successful, PRINT technology would decrease donor list wait times, reduce the need and cost for immunosuppressive drugs, and make organs and tissues more widely available for patients across the country.

ADAPT aims to bring together researchers in systems biology, bioinformatics, mathematical modeling, and oncology to address the challenge of treating ever-changing metastatic cancer. To meet this goal, the ADAPT program invites proposals to three technical areas. Technical area 1 focuses on therapy recommendation techniques, including multi-modal data fusion, resistant trait modeling, and development of biomarkers to predict drug response. Technical area 2 focuses on a new evolutionary clinical trial that treats patients during multiple therapy lines by discovering emergent resistant traits and therapy biomarkers developed in technical area 1. Technical area 3 unites researchers and clinicians through the creation of a cancer treatment and analysis platform to enable real-time data availability. The goal of the program is to accurately predict which patients will respond to which therapies, improving survival in people with metastatic cancers.

The Engineering of Immune Cells Inside the Body, or EMBODY, program aims to develop an adaptable, low-cost platform where cells in the body are given instructions to adjust their behavior. By moving the creation of specially trained immune cells out of the lab and in vivo, this platform could eliminate the time, cost, and access hurdles faced by traditional immune cell therapy manufacturing.

The ARPA-H Sprint for Women’s Health’s new request for solutions (RFS) funding opportunity seeks unconventional approaches and innovative new avenues to push high-impact biomedical research forward to improve women’s health outcomes. The Sprint for Women’s Health will use two funding tracks to foster transformative research and development efforts. One for early-stage research, or “Spark” solutions and the other for later-stage development, or “LaunchPad” solutions.

As a nonprofit organization, MTF Biologics reinvests to positively affect lives across the globe by offering Allograft Innovation Grants for funding translational and clinical research to advance Allograft Tissue Transplantation and support our mission to Save and Heal Lives. Funding is available for both Allograft Translational Research and Allograft Clinical Research projects. Awarded grants are aimed at advancing allograft tissue transplantation science and patient care. Submitted research projects must utilize allografts or allograft-derived materials, and must have a strong clinical translation component. Clinical areas of interest include: Orthopedics, Spine, Sports Medicine, Plastic & Reconstructive Surgery, Aesthetics, Surgical Soft Tissue Repair and Reconstruction, Wound Care, or other areas which utilize allograft transplant technologies.

To advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP)), the foundation established the MDS Research Fund (MDSRF).

Notification of acceptance or rejection of abstracts will be e-mailed in April 2024. The final selection of abstracts for presentation and placement of accepted abstracts in the program format will be made by the Program Committee of each regional host.

EGFL6 – a poorly studied stem cell regulatory factor – is known to regulate not only ovarian cancer stem-like cell migration and differentiation but also tumor angiogenesis. However, it remains unclear how EGFL6 impacts the immune system. In this research proposal, the investigators will use genetic and pharmacologic approaches to determine which integrins mediate Egfl6-dependent bone marrow granulocytic and monocytic cell proliferation, migration and their differentiation into myeloid-derived suppressor cell and tumor-associated macrophage phenotypes.

The Advanced Research Projects Agency for Health (ARPA-H) is hosting a hybrid Proposers’ Day in support of a planned solicitation for the Resilient Extended Automatic Cell Therapies (REACT) program. The Proposers’ Day will be held virtually and in-person on November 16, 2023, from 8:30 AM to 5:30 PM Mountain Time (MT) in Denver, Colorado.

MTRAC and Kickstart awards are part of the University of Michigan MTRAC for Life Sciences Innovation Hub, a statewide program that supports translational research projects in life sciences with high commercial potential, opens July 2023.

The Michigan Translational Research and Commercialization (MTRAC) for Life Sciences Innovation Hub is a statewide program supporting translational research projects in life sciences with high commercial potential, with the ultimate goal of positively impacting human health. Innovators from all schools at the University of Michigan, other institutions of higher education, non-profit research centers, and hospital systems across Michigan are eligible to submit projects for funding consideration.

What if surgeries fixed problems flawlessly, the first time? Precision Surgical Interventions (PSI) aims to help all surgical procedures reach their intended goal with no errors and no need for re-operation. The program aims to develop solutions to two major surgical problems: tumor edge visualization and critical anatomy visualization.

Repairing the Extracellular Matrix: Request for Proposal

ARPA-H has officially launched its first program-specific broad agency announcement (BAA): Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO). NITRO aims to revolutionize care for the 32.5 million Americans suffering from osteoarthritis (OA) through groundbreaking approaches to tissue regeneration. NITRO anticipates that teaming will be necessary to achieve the goals of the program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal to the NITRO BAA. Multiple awards and award types are anticipated under the NITRO BAA. For full program details, please see the linked BAA and additional information below. Those interested in NITRO should read the full BAA and contact ARPA-H at NITRO@arpa-h.gov about joining the program.

The Advanced Research Project Agency for Health (ARPA-H) has released a new announcement for an SBIR solicitation. This solicitation invites proposals in the following areas: 1. ARPA-H 01 – Novel telehealth instruments for assessing pediatric well-being. 2. ARPA-H 02 – Microneedle-based patches and digital patch interfaces for remote and real-time transdermal drug delivery and chronic disease management. 3. ARPA-H 03 – Robotics for autonomous soft tissue surgery. 4. ARPA-H 04 – Intra-operative contrast agents. 5. ARPA-H 05 – Scale-Up: Transition disruptive technologies from proof-of-concept prototypes to commercially scalable and deployable technologies.

The FSHD Society offers investigator-initiated research grants to support basic, translational and clinical-based research in facioscapulohumeral muscular dystrophy (FSHD).

The field of biomaterials has grown from a niche within materials science to a robust discipline that has enabled significant biomedical advances. However, a major gap still exists between exciting advances in materials science and tailoring these advances towards biomedical problems.

Kickstart Awards offer early-stage project funding, enabling biomedical innovators to develop proof of concept for technologies. This award is aimed at enhancing the commercialization potential of technology from any Michigan-based non-profit institution to the point of demonstration of utility and possible inclusion in the MTRAC Life Sciences or other funding programs. Awards, which are up to $42,500, have a cost share requirement. To be eligible for the Kickstart program, an invention disclosure needs to be filed with an innovator's institution.

The Michigan Translational Research and Commercialization for Life Sciences Innovation Hub is a statewide program supporting translational research projects in life sciences with high commercial potential, with the ultimate goal of positively impacting human health. Innovators from all schools at the University of Michigan, other institutions of higher education, non-profit research centers, and hospital systems across Michigan are eligible to submit projects for funding consideration.

NETRF seeks proposals uncovering the molecular and genetic basis of NETs, and the underlying processes driving tumor initiation and progression. We encourage mechanistic studies of NETs at multiple levels (genetic, epigenetic, proteomic, phosphoproteomic, kinomic, and/or metabolomic) and exploration / discovery of associated therapeutic opportunities. Emphasis on GI NETs is highly encouraged.

Nominations for the ARPA-H Dash will be accepted through an online portal for review between March 29 and April 7, 2023. Each submission should include a piece of evidence with citation, published after January 1, 2018, a short descriptive title for display in the brackets, identification of which ARPA-H focus area is targeted for transformation, and answers to three questions about the proposed transformation.

The objective of the Janice Wiesman Young Investigator Grant Program is to provide funding to researchers at eligible academic or nonprofit institutions who submit innovative research proposals in the areas of translational, clinical, or applied research. The research should advance the understanding of ATTR amyloidosis, facilitate early diagnosis of patients with ATTR amyloidosis, and/or enhance management of patients with a diagnosis of ATTR amyloidosis. Specifically, this program will support two young investigators, such as current fellows, residents, or junior faculty, annually to promote quality research related to ATTR amyloidosis and to support the development of future researchers and clinicians.

This Funding Opportunity Announcement (FOA) announces the renewal of the NIH Research Evaluation and Commercialization Hub (REACH) program, established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIH’s mission.

OREF, in partnership with the Musculoskeletal Transplant Foundation (MTF Biologics) solicits investigator-initiated research proposals focusing on research in the science of biologic—reconstruction, bone regeneration, transplantation—allografts, including stem cells for graft transplantation.

Given the breadth of the discipline, the PhRMA Foundation’s Translational Medicine Program focuses specifically on novel research that uses the “bedside to bench” approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation seeks research proposals that focus on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management. Applicants should work with clinical collaborators to identify unmet clinical needs. Proposals should integrate innovative technologies, with advanced biological, chemical, diagnostic, and pharmacological sciences and engineering methodologies

The PhRMA Foundation’s Postdoctoral Fellowship in Translational Medicine supports individuals (U.S. and non-U.S. citizens) engaged in a multidisciplinary, collaborative research training program at an accredited U.S. university that will extend their credentials in translational medicine.

The Ruth K. Broad Biomedical Research Foundation, Inc., a support corporation of Duke University, funds research in the neurosciences with a specific focus on investigation that may advance the knowledge or treatment of Alzheimer’s disease. Pilot studies that can lead to conventional funding are preferred, to focus the Foundation’s support on new rather than existing research.

The Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine represents a joint effort to encourage and support postdoctoral or clinical research fellows to conduct highly novel and provocative research in the field of regenerative cancer medicine and to establish a successful career path in this field. Funded research is directly related to the enhancement of the physiology of cancer survivors.

NYSCF is soliciting applications from early career investigators for awards to support translational stem cell research. The aim of this initiative is to support highly innovative, emerging scientists whose pioneering approaches have the potential to transform the field of stem cell research, and that leverage stem cells to advance the understanding and treatment of human disease.

The purpose of this Notice of Special Interest (NOSI) is to promote research focused on the development, adaptation, or integration of innovative biomaterials for cancer biology. The applications of these new materials are expected to enable new insights into basic cancer research.

Career Development Grant

The IADR Osteology Foundation New Investigator Award in Oral Tissue Regeneration is jointly sponsored by the International Association for Dental Research (IADR) and the Osteology Foundation, with funding provided exclusively by the Osteology Foundation.

The PKD Foundation’s principal mission is to support basic, translational and clinical research that will benefit patients with autosomal dominant and autosomal recessive polycystic kidney disease (ADPKD and ARPKD).

The McKnight Scholar Awards are given to exceptional young scientists who are in the early stages of establishing an independent laboratory and research career. The intent of the program is to foster the commitment by these scientists to research careers that will have an important impact on the study of the brain.

The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center is one of the two national Resource Centers established by the National Institute of Dental and Craniofacial Research (NIDCR)’s Dental Oral and Craniofacial Tissue Regeneration Consortium (DOCTRC) initiative. With the overarching goal of developing clinical trial-ready tissue engineering/ regenerative medicine products and protocols, the DOCTRC initiative is providing funding and resources through the Interdisciplinary Translational Project (ITP) program administered by the two national Resource Centers. The MPWRM Resource Center brings together a multi-disciplinary team of clinicians, engineers, scientists, and technology commercialization and regulatory experts from academia and industry to support the regenerative medicine research community by providing resources and expertise to guide innovations that address unmet clinical needs for the regeneration or restoration of DOC tissues.

Michigan Drug Discovery Screening Grants include both funding and scientific support for high-throughput screening of small molecules or natural product extracts with the goal of identifying chemical matter for modulating novel therapeutic targets. At the end of the grant, researchers should have identified and confirmed a set of high-quality hit compounds with the potential to be further developed into tool compounds and therapeutic agents. To be eligible for funding, the proposal must present a clear statement of the scientific hypothesis to be tested, supported by strong target validation or phenotypic data. A prerequisite for funding is a validated screening assay requiring minimal optimization, e.g., translation from 96-well to 384-well format.

The University of Michigan has again been invited to submit nominees for the prestigious HHMI Gilliam Fellowship for Advanced Study. This fellowship is awarded to student-mentor pairs and we are able to nominate five such pairs. Prospective fellows must be (i) U.S. citizens, U.S. permanent residents, undocumented childhood arrivals, or undocumented individuals who have been granted temporary permission to stay in the US (DACA), and (ii) from populations excluded from and underrepresented in science because of ethnicity, race, or disability status, or Alumni of the HHMI EXROP program, and (iii) at the appropriate stage of their PhD training.

The MICHR Accelerating Synergy Award is designed to support interdisciplinary research teams in pursuing external multi-component large-scale grants (eg, NIH P01, P30, P50, U24, U54, UM1). Being competitive for large-scale grants requires significant advanced planning, a well-defined and central research theme, strong preliminary data, and a history of partnership among collaborating investigators.

The U-M Injury Prevention Center (IPC) anticipates funding 3-6 one-year exploratory project awards in 2022 that have the greatest potential to advance injury prevention science. Awards will be in the amount of either $25,000 or $50,000 per award, and are expected to have a focus on: a) the development and evaluation of primary prevention strategies, programs, and policies; and/or b) the dissemination, implementation, and translation of evidence-based injury prevention strategies.

This Request for Proposals (RFP) from Cures Within Reach (CWR) is seeking clinical repurposing trials in any disease led by a racial / ethnic minority that is underrepresented in biomedical research (as defined by the NIH; https://grants.nih.gov/grants/guide/notice-files/NOTOD-20-031.html).

Grant proposals may be in the areas of basic biomedical or clinical research and should address key questions regarding the pathogenesis, diagnosis, prevention, or treatment of diabetes, its complications, or related endocrine or metabolic disorders (for example: obesity, metabolic syndrome, counter-regulatory proteins).

DISP proposals should be for two years of support, with total requested funding up to $100,000 direct costs. That is, the combined budgets proposed for all Co-Principal Investigators must not exceed a total of $100,000 for the two-year period.

The Kickstart Awards offer funding up to $42,500, with all awarded projects requiring a cost share from the investigator/institution. Proposals must address a discrete milestone that is critical to the advancement of research to the point of product development. This milestone will increase the commercialization potential of the overall research project to the point where it can be considered a strong candidate for further translational research funding and ultimately commercialization. Examples include in-vivo testing, prototype development, beta development and testing, or drug-candidate pre-clinical work.

We are calling for proposals for the 2021 SVRF that address the following research focus area: Identification and investigation of cardiac developmental pathways and mechanisms to increase fundamental knowledge of heart development; applied, but not limited, to the following areas of interest: Pre- and neonatal physiology Developmental systems biology Remodeling potential and plasticity Mechanical, genetic, and biological factors Cardiogenesis and cell fate Placental and maternal health

JDRF is committed to the development of devices to improve health outcomes in people with type 1 diabetes (T1D). Diabetic ketoacidosis (DKA) is a dangerous acute complication of T1D that is insufficiently addressed or even sometimes exacerbated by current therapeutic options. To fill this gap, JDRF invites applications to develop continuous ketone monitor (CKM) functionality in continuous glucose monitor (CGM) devices to warn users of impending DKA events and allow preventive actions to be taken. Each application may request up to $200,000 per year (including up to 10% indirect costs), for up to two years.

The 2021 Michigan AgBio Innovation Challenge invites researchers at public universities, non-profit research institutes and public hospitals across the state of Michigan to do some real-time opportunity assessment and technology pathfinding in the AgBio market space.

NIST invites Manufacturing USA institutes to propose high-impact projects designed to fund awards for research, development, and testbeds to prevent, prepare for, and respond to coronavirus.

The mission of the Breast Cancer Alliance (BCA) is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure. To promote these goals, we invest in innovative research, breast surgery fellowships, regional education, dignified support and screening for the underserved.

NCI SBIR encourages small businesses developing highly innovative and transformative technologies that have the potential to create new scientific paradigms, establish entirely new and improved approaches to significantly improve cancer research, prevention, detection and care in pediatric and/or rare cancers to apply for the NCI SBIR Innovative Concept Award.

Science & SciLifeLab Prize for Young Scientists Applicants are to submit a 1000-word essay that is judged by an independent editorial team organized by the journal Science. Essays are judged on the quality of research and the applicants’ ability to articulate how their work would contribute to the scientific field. This year’s application period is March 15 – July 15, 2021.

The Young Investigator grant is a three-year award designed to support early career researchers, such as postdoctoral, clinical fellows or instructors, pursuing promising childhood cancer research ideas. These grants aim to cultivate the best and brightest researchers of the future who demonstrate a commitment to a research career in pediatric cancer. A mentor is required, and a career development plan must be included.

Applicants should have a track record of conducting high-quality research and an interest in pursuing a significant shift in their trajectories as researchers. We recognize that early-career researchers are rarely given incentives or support to take measured risks in their work, so this award includes a mentoring component, as well as a supportive academic community.

In this spirit, Baxter's Young Investigator Awards seek to stimulate and reward research applicable to the development of therapies and medical products that save and sustain patients' lives. We invite current graduate students and postdoctoral fellows to submit descriptions of ongoing research. The Baxter Young Investigator Awards program consists of two tiers: first-tier awards include a $3,000 cash prize and an onsite visit to Baxter to present the award-winning research; second-tier awards receive a $500 cash prize. Prizes are granted based on merit of the research.

The BBVA Foundation Frontiers of Knowledge Awards recognize fundamental contributions in a broad array of areas of scientific knowledge, technology, humanities and artistic creation, as listed in point 2 of these call conditions.

The Advanced Postdoctoral Fellowship program is designed to attract qualified and promising health scientists, to provide an opportunity to receive full time research training, and to assist these promising individuals in transitioning from a fellowship to an independent (faculty-level) position. JDRF envisions the 3-year award term as a period in which fellows will receive critical research training that will position them to work at the leading edge of their chosen field. An additional, optional 1-year transition award will further assist fellows to proceed to independent faculty or research appointments and will serve as a bridge between the fellowship and independent competitive research funding.

The American Diabetes Association is requesting applications for research focused on the impact of diabetes on health disparities and, the impact of health disparities on diabetes and its complications. The goal of this RFA is to identify grants of the highest scientific merit, with greatest potential for successful outcomes and most innovative and transformative, for funding. The breakdown of targeted grant types is: Innovative Clinical or Translational Science, Junior Faculty Development and Postdoctoral Fellowship Awards.

These awards support early investigators as they establish independence as diabetes researchers with a focus on health disparities. Refer to the ADA Health Disparities and Diabetes Research Award RFA(link is external) for further details.

The American Medical Association is pleased to announce a request for applications for its Accelerating Change in Medical Education Innovation Grant Program. The program’s $30,000 grants aim to hasten the transformation of medical education by supporting the research, implementation and expansion of key innovations and initiatives developed through the AMA “Accelerating Change in Medical Education” initiative, including: Health systems science Coaching in support of competency development Transitions along the medical education continuum The master adaptive learner model Improving diversity in medical education

One-year grants of up to $300,000 per project; Regenerative medicine/ tissue engineering therapies for dental, oral, and craniofacial applications

Innovator Awards are open to researchers who are developing healthcare innovations that could have a major and measurable impact on human health.

Projects responsive to this solicitation must aim to establish a robustly validated and reproducible set of differentiation design rules, mechanistic models, real-time sensing, control, and quality assurance methods, and integrate them into a workable differentiation strategy. They must deepen our fundamental understanding of how cells develop and differentiate, providing insights into mechanisms, molecular machinery, dynamics, and cell-cell and cell-extracellular matrix (ECM) interactions, and use this understanding to manipulate cells purposefully.

We are pleased to announce a competition for Pre-doctoral and Non-traditional postdoctoral Fellowships in Organogenesis as part of a NIH T32 Training Grant (Training Program in Organogenesis). The goal of the fellowship awards are to provide up to two years of support for outstanding scholars who wish to undertake a research project in the field of organogenesis.

The Training Program in Organogenesis is a University-wide predoctoral and postdoctoral training program that offers a range of fellowships to training grant eligible students. The Training Program in Organogenesis offers federally funded Pre and Postdoctoral fellowships, Non-Traditional Postdoctoral fellowships co-sponsored by the Medical School and Dental School.

The award is presented for outstanding research performed by the applicant as described in a 1,000-word essay.

Precision Health at U-M is a population-based, data-driven strategy that uses advanced tools and technology to consider more information about a patient than has traditionally been examined, such as genetic, lifestyle, and environmental factors. These data are used to discover what influences disease development and progression, which will allow researchers to devise approaches to prevent disease, create novel treatments, and craft a process by which to implement discoveries at the point of care.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease.

The Frankel Innovation Initiative encourages U-M faculty to collaborate with experts at U-M and outside institutions in order to help quickly move early-stage research to results that positively affect human health and save lives.

Michigan Drug Discovery Screening Grants include both funding and scientific support for high-throughput screening of small molecules or natural product extracts with the goal of identifying chemical matter for modulating novel therapeutic targets. At the end of the grant, researchers should have identified and confirmed a set of high-quality hit compounds with the potential to be further developed into tool compounds and therapeutic agents. To be eligible for funding, the proposal must present a clear statement of the scientific hypothesis to be tested, supported by strong target validation or phenotypic data. A prerequisite for funding is a validated screening assay requiring minimal optimization, e.g., translation from 96-well to 384-well format.

The Project Grants will advance projects for which compounds active against the intended biological target have been already identified, as well as projects that can benefit from the combined expertise and capabilities of multiple drug discovery experts. U-M researchers working across all therapeutic areas are eligible for a project grant. Funded projects will be conducted in partnership with Michigan Drug Discovery. Project teams that have already successfully completed a Michigan Drug Discovery supported screening campaign are encouraged to apply for Project Grants. However, prior support through Michigan Drug Discovery is not a prerequisite.

The Catalyst Award aims to support early career faculty (at the Assistant Professor or earlier ranks) in advancing their translational research careers. Applicants should propose a research plan that will help them to generate the data needed to strengthen hypotheses for subsequent extramural applications. We encourage applications for innovative projects at all stages of translation (T1-T4) that use one of the following approaches to research: investigator-initiated research or community-based participatory research (CBPR).

This Funding Opportunity Announcement (FOA) invites applications for Centers of Research Translation (CORT). Overall, a CORT research program should be carried out by a synergistic team of scientists who, through an interdisciplinary team science approach, will address a highly significant translational research challenge in a single or a group of highly-related disease(s) or condition(s) within the mission of the NIAMS.

The Grant supports university-level multidisciplinary scientific studies on viral and bacterial infection-induced cancers. We welcome graduate student and post doctoral scientists from chemistry, pharmacology, biochemistry, engineering, biology, and any related disciplines to apply.

Three innovator awards will be granted with one awarded at the faculty, graduate student, and postdoctoral level, respectively. There will be a fourth award added to recognie a person who is making a difference in the BI community.

The Coulter Program collaboratively works with UM faculty to develop medical device concepts invented at UM and license the related IP rights to medical device companies who complete development and seek FDA approvals. The Coulter Program now requires an LOI prior to receiving an invitation to submit a project proposal. The Coulter Program has two award programs – Enlighten and Evolve. Enlighten Award: Awardees receive direct mentoring from medical device industry experts and outside investors, market, regulatory and IP landscape assessments, and introductions to medical device companies. Program deliverables culminate with product strategic plans. Enlighten awardees will be invited to pitch for Evolve Awards to execute on strategic plans. Evolve Award: Uncover – New product design planning, early prototyping and verification studies. Emerge –Advanced prototype development, FDA interactions, validation studies (bench, animal, human), and partnering meetings with medical device companies.

The SPARC-MDD Partnership Grant provides funding and collaborative support for therapeutics projects led by U-M faculty. Selected projects have the potential to receive the equivalent of up to $1.5 million over a three-year period, including in-kind support in areas such as medicinal chemistry and preclinical development.

This Funding Opportunity Announcement (FOA) aims to support early career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses.

A competition to accelerate artificial kidney development toward human clinical trials. Phase 1 of the Artificial Kidney Prize seeks solutions that enable and advance the functionality, effectiveness, and/or reliability of artificial kidneys.

The Michigan Translational Research and Commercialization (MTRAC) Innovation Hub for Ag & Bio is the first in a series of specialized statewide commercialization programs with in-depth domain expertise in specific areas of research. Translational research funding to accelerate the commercialization of high potential Ag & Bio technology is available to innovators at institutions of higher education, non-profit research centers, and hospital systems throughout Michigan.

In response to a 2017 study from the National Academies of Sciences, Engineering, and Medicine (NASEM), the Engineering Research Centers (ERC) program piloted a planning grant opportunity in 2018. This solicitation is a continuation of this pilot program.

The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support 1) research on bioethical issues to develop or support the development of an evidence base that may inform future policy directions, and/or 2) certain efforts to develop or augment bioethics research capacity. Applicants may propose to supplement parent awards focused on bioethics or to add a component related to bioethics to a parent award in which bioethics was not the focus. Note that applications must be within the general scope of the parent award.

Tissue Engineering and Regeneration (TEAM) is an interdisciplinary research-intensive training program for individuals who wish to pursue careers in the oral sciences with a focus in the area of restoration of oral-craniofacial tissues.

The National Institutes of Health (NIH) launched the Rapid Acceleration of Diagnostics (RADxSM) initiative to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. Accurate, fast, easy-to-use, and widely accessible testing is required before the nation can safely return to normal life.

This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices.

The Kickstart Awards offer funding up to $42,500, with all awarded projects requiring a cost share from the investigator/institution. Proposals are reviewed and awarded semi-annually, with due dates on February 1 and August 1. All interested researchers must complete a pre-submission application before submitting a full proposal.